@article{jfnr20221016,
author={{Hassan, Hesham Fathy Hassan and Mansour, Ahmed Mohamed and El-Sayed, El-Sayed Mohamed},
title={Orlistat and Hydroxycitrate Ameliorate Colon Cancer in Rats: The Impact of Inflammatory Mediators},
journal={Journal of Food and Nutrition Research},
volume={10},
number={1},
pages={41--49},
year={2022},
url={http://pubs.sciepub.com/jfnr/10/1/6},
issn={2333-1240},
abstract={Colon cancer (CC) is the third type of cancer worldwide. This study aimed to investigate the possible protective effects of orlistat and hydroxycitrate (HCA) against dimethylhydrazine (DMH) and high-fat diet (HFD)-induced CC in adult male rats. The rats were divided into ten groups including the normal group. The rats were treated with the DMH/HFD, orlistat (32 mg/kg), orlistat/DMH, orlistat/DMH/HFD, HCA (135 mg/kg), HCA/DMH, HCA/DMH/HFD, DMH (40 mg/kg), and HFD (20%) for 16 weeks. Administration of orlistat and HCA improved the measured markers of a colon tumor, inflammatory mediators, oxidative stress, as well as caspase-3 (an apoptotic marker) in the colon tissue compared with the CC group. Furthermore, orlistat and HCA corrected the histopathological lesions in the colon lining. These findings revealed that orlistat and HCA had a positive chemopreventive efficacy and could be viewed as a possible clinical solution for colon cancer.},
doi={10.12691/jfnr-10-1-6}
publisher={Science and Education Publishing}
}